MedTrace Logo

Dynamic Circulating Tumor Cell (CTC) Changes During the Chemotherapy in NSCLC

NCT01740804 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2016-12-05

No results posted yet for this study

Summary

Primary endpoint To observe the dynamic changes of CTC during the process of platinum based chemotherapy in advanced NSCLC.

To study the relationship between CTC count and clinical outcome of chemotherapy (ORR and PFS).

Secondary endpoint To study the relationship between CTC and overall survival. To study the molecular feature of CTC, such as epidermal growth factor receptor (EGFR), KRAS, CD117, etc.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Cell, Circulating Tumor

Sponsors & Collaborators

  • Guangdong Association of Clinical Trials

    lead OTHER

Principal Investigators

  • Yi-Long Wu, MD · Guangdong General Hospital & Guangdong Academy of Medical Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2016-04-30
Completion
2016-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01740804 on ClinicalTrials.gov